NEW YORK----In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper's account.
SAN ANTONIO----Pfizer Inc. today announced results from studies evaluating neratinib , an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium .
No comments:
Post a Comment